Upon treatment of BV-173 and TOM-1 cell lines with CEL_Amide, we observed degradation of LIMK1, whereas the LIMK2 protein was left unaffected, suggesting a possible role of LIMK1 in leukemic maintenance in BCR::ABL+ ALL. Here, LIMK1 is linked to acute lymphoblastic leukemia.